Atrium Therapeutics launches as independent RNA therapeutics company for rare cardiomyopathies.
ByAinvest
Friday, Feb 27, 2026 9:26 am ET1min read
RNA--
RNAM--
Atrium Therapeutics, a new publicly traded company, has been spun off from Novartis AG's acquisition of Avidity Biosciences. The company focuses on precision cardiology programs using targeted RNA delivery. Lead candidates ATR 1072 and ATR 1086 are expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectively. Atrium Therapeutics begins operations with $270 million in cash and cash equivalents and is led by Kathleen Gallagher as President and CEO.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet